Cited by 830HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Fry, David W., Kraker, Alan J., McMichael, Amy, Ambroso, Linda A., Nelson, James M., Leopold, Wilbur R., Connors, Richard W., Bridges, Alexander J.·1994·Science

DOI 10.1126/science.8066447

Open this paper in CoChat — free account

Abstract

A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concentrations. PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.

Integrity signals

Registry

Crossref · 10.1126/science.8066447

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C. F., Duckworth, B. C., Graziani, A., Kapeller, R., & Soltoff, S. P. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,697
Growth Factors and Cancer
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,017
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,418
RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. F. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,282
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 815
Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast
Sandgren, E. P., Luetteke, N., Palmiter, R. D., Brinster, R. L., & Lee, D. C. (1990) · Cell · doi:10.1016/0092-8674(90)90075-p · Cited by 752
TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas
Jhappan, C., Stahle, C., Harkins, R. N., Fausto, N., Smith, G. H., & Merlino, G. T. (1990) · Cell · doi:10.1016/0092-8674(90)90076-q · Cited by 709
DIOGENES SYNDROME
Clark, A. N. G., Mankikar, G. D., & Gray, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91280-5 · Cited by 697
EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS
Neal, D. E., Bennett, M., Hall, R. R., Marsh, C., Abel, P., Sainsbury, J. R. C., & Harris, A. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91386-8 · Cited by 604
Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies
Masui, H., Kawamoto, T., Sato, J., Wolf, B., SATO, G. H., & Mendelsohn, J. M. (1984) · The Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

HENDLER, F. J., Increased EGF-R1 binding predicts a poor survival in squamous tumors, CANCER CELLS 7: 347 (1989).

Sorted by citations

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,374
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,232
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1
Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., & Lee, J. C. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
STATs in oncogenesis
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 939
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Distinct Neural Stem Cells Proliferate in Response to EGF and FGF in the Developing Mouse Telencephalon
Tropepe, V., Sibilia, M. C., Ciruna, B. G., Rossant, J., Wagner, E. F., & van der Kooy, D. (1999) · Developmental Biology · doi:10.1006/dbio.1998.9192 · Cited by 819
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 615
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J. A., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 594
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H., Hsu, S.-C., Ali‐Seyed, M., Gündüz, M., Xia, W., Wei, Y., Bartholomeusz, G. A., Shih, J. Y., & Hung, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 556
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.
Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J., & Hubbard, S. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 492
Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: Synthetic approaches and multifarious applications
Khan, I. A., Ibrar, A., Abbas, N., & Saeed, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.005 · Cited by 472
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 464
Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: The advances continue
Khan, I. A., Ibrar, A., Ahmed, W., & Saeed, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.084 · Cited by 431
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A. M., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 424
Self-citation
THE CROONIAN LECTURE 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease
Hunter, T. R. (1998) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1998.0228 · Cited by 414
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 400
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
Traxler, P. M., & Furet, P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00044-8 · Cited by 390
STAT signaling in head and neck cancer
Song, J. I., & Grandis, J. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203483 · Cited by 374
Homogeneous and heterogeneous catalysts for multicomponent reactions
Climent, M. J., Corma, A., & Iborra, S. (2011) · RSC Advances · doi:10.1039/c1ra00807b · Cited by 374
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain11Edited by B. Holland
Moriki, T., Maruyama, H., & MARUYAMA, I. N. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4923 · Cited by 350
The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn, J. M. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080003 · Cited by 330
Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids
Auti, P. S., George, G., & Paul, A. T. (2020) · RSC Advances · doi:10.1039/d0ra06642g · Cited by 328
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 304
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 297
Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: An update on the development of synthetic methods and pharmacological diversification
Khan, I. A., Zaib, S., Batool, S., Abbas, N., Ashraf, Z., Iqbal, J., & Saeed, A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.031 · Cited by 281
ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding
Low-Nam, S. T., Lidke, K. A., Cutler, P. J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Wilson, B. S., & Lidke, D. S. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2135 · Cited by 273
Tethered Epidermal Growth Factor Provides a Survival Advantage to Mesenchymal Stem Cells
Fan, V. H., Au, A., Tamama, K., Littrell, R., Richardson, L. B., Wright, J. W., Wells, A. H., & Griffith, L. G. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0320 · Cited by 268
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox, A. D., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00011-5 · Cited by 268
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal, G. W., Honsawek, S., Litz, J., & Buchdunger, E. (2000) · PubMed · Cited by 265
Inhibitors of protein kinases and phosphatases
MacKintosh, C., & MacKintosh, R. W. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90127-9 · Cited by 264
Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
Dong, J., Opresko, L. K., Dempsey, P. J., Lauffenburger, D. A., Coffey, R. J., & Wiley, H. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6235 · Cited by 262
HB-EGF is Necessary and Sufficient for Müller Glia Dedifferentiation and Retina Regeneration
Wan, J., Ramachandran, R., & Goldman, D. (2012) · Developmental Cell · doi:10.1016/j.devcel.2011.11.020 · Cited by 262
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript EGFR inhibitor PD153035 (Fry et al., 1994; Fry et al., 1997), the MAPK (ERK1 and 2) inhibitors PD98059 (Dudley et al., 1995) or SL327 (Atkins et al., 1998) and DMSO in separate experiments.”
BackgroundInfluential
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer
Scholz, A., Heinze, S., Detjen, K. M., Peters, M., Welzel, M., Hauff, P., Schirner, M., Wiedenmann, B., & Rosewicz, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01064-3 · Cited by 255
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M., Cadoni, G., Benedetti-Panici, P., Paludetti, G., Scambia, G., & Mancuso, S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.525 · Cited by 249
Reaching out for signals
Lidke, D. S., Lidke, K. A., Rieger, B., Jovin, T. M., & Arndt‐Jovin, D. J. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503140 · Cited by 229
Profiling receptor tyrosine kinase activation by using Ab microarrays
Nielsen, U. B., Cardone, M. H., Sinskey, A. J., MacBeath, G., & Sorger, P. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633513100 · Cited by 226
Design of allele-specific inhibitors to probe protein kinase signaling
Bishop, A. C., Shah, K., Liu, Y., Witucki, L. A., Kung, C.-Y., & Shokat, K. M. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70198-8 · Cited by 226
Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
Kumar‐Sinha, C., Ignatoski, K. W., Lippman, M. E., Ethier, S. P., & Chinnaiyan, A. M. (2003) · PubMed · Cited by 222
Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways
Wang, H., Ubl, J. J., Stricker, R., & Reiser, G. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00001.2002 · Cited by 217
Hypermethylation of the APC (adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma
Hiltunen, M., Alhonen, L. I., Koıstınaho, J., Myöhänen, S., Pääkkönen, M. E., Marin, S., Kosma, V.-M., & Jänne, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970317)70:6 · Cited by 192
ErbB-targeted therapeutic approaches in human cancer
Arteaga, C. L. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00104-0 · Cited by 214
Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents
Levitzki, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00066-7 · Cited by 214
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 214
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling
Hou, D., & Kumamoto, T. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2816 · Cited by 216
Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis.
Berryman, M. A., Gary, R. K., & Bretscher, A. P. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.5.1231 · Cited by 207
Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity
Busse, D., Doughty, R. S., Ramsey, T. T., Russell, W. E., Price, J. O., Flanagan, W. M., Shawver, L. K., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6987 · Cited by 205
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
Blair, J. A., Rauh, D., Kung, C. K.-H., Yun, C., Fan, Q.-W., Rode, H. B., Zhang, C., Eck, M. J., Weiss, W. A., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio866 · Cited by 204
Quinazoline derivatives: synthesis and bioactivities
Wang, D., & Gao, F. (2013) · Chemistry Central Journal · doi:10.1186/1752-153x-7-95 · Cited by 199
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos, M., Mendelsohn, J. M., Kim, Y. M., Albanell, J., Fry, D. W., & Baselga, J. M. (1997) · PubMed · Cited by 199
Self-citation
Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases
Lawrence, D. S., & Niu, J. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00052-1 · Cited by 200
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
Ciardiello, F. (2000) · Drugs · doi:10.2165/00003495-200060001-00003 · Cited by 194
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 195
Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1387 · Cited by 196
Characterization of Chemical Libraries for Luciferase Inhibitory Activity
Auld, D. S., Southall, N. T., Jadhav, A., Johnson, R. L., Diller, D., Simeonov, A. M., Austin, C. P., & Inglese, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701302v · Cited by 183
Small Molecules as Inhibitors of Cyclin‐Dependent Kinases
Huwe, A., Mazitschek, R., & Giannis, A. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200540 · Cited by 187
Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck
Xi, S., Zhang, Q. H., Dyer, K. F., Lerner, E. C., Smithgall, T. E., Gooding, W. E., Kamens, J., & Grandis, J. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303499200 · Cited by 181
Copper-catalyzed annulation of amidines for quinazoline synthesis
Lv, Y., Li, Y., Xiong, T., Pu, W., Zhang, H., Sun, K., Liu, Q., & Zhang, Q. (2013) · Chemical Communications · doi:10.1039/c3cc43129k · Cited by 178
The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 179
Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily
Noonberg, S. B., & Benz, C. C. (2000) · Drugs · doi:10.2165/00003495-200059040-00003 · Cited by 173
Testosterone Activates Mitogen-Activated Protein Kinase via Src Kinase and the Epidermal Growth Factor Receptor in Sertoli Cells
Cheng, J., Watkins, S. C., & Walker, W. H. (2007) · Endocrinology · doi:10.1210/en.2006-1465 · Cited by 172
In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy
Xi, S., Gooding, W. E., & Grandis, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1208316 · Cited by 172
RTK mutations and human syndromes: when good receptors turn bad
Robertson, S. C., Tynan, J. A., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02077-1 · Cited by 167
EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation
Péus, D., Hamacher, K. L., & Pittelkow, M. R. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12340759 · Cited by 171
The Biochemistry of Cancer Dissemination
Price, J. T., Bonovich, M. T., Kohn, E. C., Welch, D. R., & Hershey, M. S. (1997) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239709082573 · Cited by 169
Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals
Wu, W., Graves, L. M., Jaspers, I., Devlin, R. B., Reed, W., & Samet, J. M. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.5.l924 · Cited by 167
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803785 · Cited by 166
Epidermal growth factor receptor relocalization and kinase activity are necessary for directional migration of keratinocytes in DC electric fields
Fang, K. S., Ionides, E. L., OSTER, G. F., Nuccitelli, R., & Isseroff, R. R. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.12.1967 · Cited by 164
Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor
Svegliati‐Baroni, G., Ridolfi, F., Hannivoort, R. A., Saccomanno, S., Buist‐Homan, M., Minicis, S. D., Jansen, P. L. M., Candelaresi, C., Benedetti, A., & Moshage, H. J. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.007 · Cited by 162
An in vitro tubulogenesis system using cell lines derived from the embryonic kidney shows dependence on multiple soluble growth factors
Sakurai, H., Barros, E. J. G., Tsukamoto, T., Barasch, J. M., & Nigám, S. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6279 · Cited by 160
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
Nicholson, R. I., McClelland, R. A., Robertson, J. F. R., & Gee, J. M. W. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060373 · Cited by 160
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Evidence for a size-sensing mechanism in animal cells
Dolznig, H., Grebien, F., Sauer, T., Beug, H., & Müllner, E. W. (2004) · Nature Cell Biology · doi:10.1038/ncb1166 · Cited by 156
The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells
Bowers, G. D., Reardon, D. B., Hewitt, T., Dent, P., Mikkelsen, R. B., Valerie, K. C., Lammering, G., Amir, C., & Schmidt‐Ullrich, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204255 · Cited by 153
Angiotensin II stimulates ERK via two pathways in epithelial cells: protein kinase C suppresses a G–protein coupled receptor–EGF receptor transactivation pathway
Li, X., Lee, J. W., Graves, L. M., & Earp, H. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2574 · Cited by 150
Podocytes are sensitive to fluid shear stress in vitro
Friedrich, C., Endlich, N., Kriz, W., & Endlich, K. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00196.2005 · Cited by 150
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Lu, X., Smaill, J. B., Patterson, A. V., & Ding, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01719 · Cited by 147
Role of Tyrosine Kinase Activity of Epidermal Growth Factor Receptor in the Lysophosphatidic Acid-stimulated Mitogen-activated Protein Kinase Pathway
Cunnick, J. M., Dorsey, J. F., Standley, T. B., Turkson, J., Kraker, A. J., Fry, D. W., Jove, R., & Wu, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14468 · Cited by 148
Self-citation
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis
Laimer, K., Spizzo, G., Gastl, G. A., Obrist, P., Brunhuber, T., Fong, D., Barbieri, V., Jank, S., Doppler, W., Rasse, M., et al. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2006.02.009 · Cited by 145
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development
Kamath, S., & Buolamwini, J. K. (2006) · Medicinal Research Reviews · doi:10.1002/med.20070 · Cited by 145
Discovering novel chemotherapeutic drugs for the third millennium
Garrett, M. D., & Workman, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00280-4 · Cited by 141
Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy
Nagy, P., Jenei, A., Kirsch, A. K., Szöllõsi, J., Damjanovich, S., & Jovin, T. M. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.11.1733 · Cited by 143
LEUKOCYTE PROTEIN TYROSINE KINASES:Potential Targets for Drug Discovery
Bolen, J. B., & Brugge, J. S. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.371 · Cited by 143
Copper-Catalyzed Synthesis of Quinazoline Derivatives via Ullmann-Type Coupling and Aerobic Oxidation
Wang, C., Li, S., Liu, H., Jiang, Y., & Fu, H. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo101685d · Cited by 142
RTK mutations and human syndromes
Robertson, S. C., Tynan, J. A., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02021-7 · Cited by 143
Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells
Alper, Ö., Bergmann‐Leitner, E. S., Bennett, T. A., Hacker, N. F., Stromberg, K., & Stetler‐Stevenson, W. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1375 · Cited by 141
Synthesis and Target Identification of Hymenialdisine Analogs
Wan, Y., Hur, W., Cho, C. Y., Liu, Y., Adrian, F. J., Lozach, O., Bach, S., Mayer, T., Fabbro, D., Meijer, L., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.01.015 · Cited by 140
EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase–Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas
Xu, K., & Shu, H. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0141 · Cited by 139

Authors: Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J.
Affiliations: Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105.
ORCID: Nelson, James M.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 1994-08-19
Volume: 265
Issue: 5175
Pages: 1093-1095
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.8066447
OpenAlex: W2069637592
Cited by: 806
References: 28
Citations by year: 2026: 8 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 10 · 2021: 12 · 2020: 19 · 2019: 11 · 2018: 13 · 2017: 18 · 2016: 13 · 2015: 18 · 2014: 24 · 2013: 26 · 2012: 31
FWCI: 14.00
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: epidermal growth factor receptor, tyrosine kinase inhibitors, receptor autophosphorylation, mitogenesis, oncogenic transformation, early gene expression, small molecule inhibitors, kinase specificity
MeSH terms: Animals, Cell Transformation, Neoplastic, Epidermal Growth Factor, Humans, Kinetics, Mitosis, Phosphorylation, Platelet-Derived Growth Factor, Protein-Tyrosine Kinases, Quinazolines, Tumor Cells, Cultured, Tyrosine, Gene Expression, Fibroblast Growth Factor 2, 3T3 Cells, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks